Put It on the Board
February 2026—The CAP supports the FDA’s proposal to reclassify oncology therapeutic nucleic-acid-based test systems from class III to class II devices with 510(k) requirements.
Webinars and Sponsored Roundtables — Register Now
Tuesday, July 21, 2026, 11:00-11:30 AM CT
Learning Objectives:
- Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
- Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
- Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
2026 Issues
Traumatic brain injury biomarkers, one year in
January 2026—When new biomarkers become part of clinical practice, the fundamental question—Will this work?—soon gives way to an equally important group of interrogatives: who, what, when, where, why, and how. At Michigan Medicine, introducing two biomarkers—glial fibrillary acidic protein, or GFAP, and ubiquitin C-terminal hydrolase L1, or UCH-L1—into the emergency department to evaluate traumatic brain injury emphasized the how of the matter.
AI ‘bottleneck’: putting the algorithms to work
January 2026—For Jansen Seheult, MD, and others deeply committed to bringing artificial intelligence to the laboratory, it’s impossible to deny that algorithm development has advanced by leaps and bounds. Take Mayo Clinic in Rochester, where Dr. Seheult is medical director of digital pathology and artificial intelligence in hematopathology. More than 20 artificial intelligence algorithms are deployed across the clinical practice in pathology and laboratory medicine. Yet that’s a small fraction of all the algorithms that have been developed at the clinic.
Role of cytokine panels in post-CAR T-cell therapy toxicities
January 2026—Translating cytokine science into better cancer care was the focus of a presentation at last year’s ADLM meeting, where the toxicities associated with CAR T-cell therapy were explained with cases and the need to measure cytokines was made clear.
In new checklists, more clarity on humidity, self-collection: Also, new requirements on tube transport and nonurine body fluid crystal analysis
January 2025—In the 2025 edition of the CAP accreditation checklists are new requirements on humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens for platelet aggregation or other platelet function testing. The new checklist edition was released last year on Dec. 9.
How to validate pan-HER2 immunohistochemistry
January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.
Direct oral anticoagulants—new guidance, lab testing
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
Letters
January 2025—A retired pathologist believes pathologists should be more involved in gross examination of specimens, not just microscopic analysis. A pathologist praises the Canadian series “Coroner” for its realistic portrayal of the forensic pathology world, crediting the involvement of a real forensic pathologist as a consultant.
From the President’s Desk
January 2026—The CAP president emphasizes the importance of inspiring others in the field of pathology. This can be achieved by encouraging new voices to join the field, engaging with medical students, and actively participating in the CAP.
Clinical pathology selected abstracts
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.